Search Results - protein

36 Results

Sort By:

Peptide Hydrogels for Rate-Controlled Delivery of Therapeutics

Abstract: Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network...

Published: 4/8/2024 | Inventor(s): Joel Schneider, Stephen Miller, Yuji Yamada, Steven Tau, Julie Hixon, Wenqing Li, Caroline Andrews, Scott Walsh

Keywords(s): DEVICE, IL-7, Nanoparticle, Peptide, Peptide-based Hydrogel, Protein, Schneider, small molecule, T Cell Enhancer, Whole Cell Delivery System

Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, TherapeuticArea > Immunology

Stable, High-Yield Production of DT390-EGF Fusion Protein for Treatment of EGF-Receptor-Positive Cancers

This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and...

Published: 7/25/2024 | Inventor(s): Jung-hee Woo, David Neville, Arthur Frankel, Andrew Thorburn, Michael Glode, Thomas Flaig

Keywords(s): cancers, DT390-EGF, EGF, Fusion, POSITIVE, Protein, RECEPTOR, treatment, VCXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Oncology, Application > Therapeutics

Serum Protein Biomarkers that Predict the Response to Liver Directed Therapy in Methymalonic Acidemia (MMA) and Propionic Acidemia (PA)

Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. The most common cause of isolated MMA is genetic deficiency of the enzyme methylmalonyl-coA mutase (MUT), which, unfortunately for the affected patients, is also the most clinically severe. NHGRI scientist have discovered biomarkers...

Published: 7/25/2024 | Inventor(s): Eirini (Irini) Manoli, Charles Venditti

Keywords(s): Acidemia, Biomarkers, Directed, liver, Methymalonic, MMA, PREDICT, Protein, RESPONSE, SERUM, That, THERAPY, VPXXXX, WBXXXX, WIXXXX, XCXXXX, XEXXXX

Category(s): Application > Diagnostics, TherapeuticArea > Ophthalmology, Application > Research Materials, TherapeuticArea > Cardiology, TherapeuticArea > Oncology, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Therapeutics, TherapeuticArea > Infectious Disease

A Novel Chemical Series for Inhibiting Bromodomain-containing Protein 4 (BRD4) for Treating Cancer

This technology includes the design, synthesis, and use of a novel chemical series for multiple treatments, including for treating cancer. A series of substituted bicyclic heteroaryl small molecules were found to be a potent inhibitor of bromodomain-containing protein 4 (BRD4) for multiple uses, including cancer. A BRD4 inhibitor is in a class of drugs...

Published: 7/25/2024 | Inventor(s): David Maloney, Shyh-Ming Yang, Ajit Jadhav, Daniel Urban, Makoto Yoshioka, Jeffrey Strovel

Keywords(s): BICYCLIC, Brd4, Bromodomain-containing, Heteroaryl, Inhibitors, Protein, Substituted, VCXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Oncology, Application > Therapeutics

Potentiating Antibody Therapy by Targeting Complement Deposited on Cancer Cells

Monoclonal antibodies (mAbs) have become a mainstay of therapy for many cancers. However, antibody therapy is not completely effective in some applications due to loss of the target surface antigen on cancer cells. Such mAb-induced “escape variants” are no longer sensitive to the therapeutic mAb therapy. It was observed that the escape variants carried...

Published: 7/25/2024 | Inventor(s): Martin Skarzynski, Margaret Lindorfer, Ronald Taylor, Christoph Rader, Berengere Vire, Erika Gaglione, Haiyong Peng, Sivasubramanian Baskar, Adrian Wiestner

Keywords(s): 2JXXXX, 4GXXXX, 5OXXXX, ANTIBODY, C3, C3d, CANCER, CB1XXX, Cell, Cells, Complement, Deposited, Listed LPM Vathyam as of 4/15/2015, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Potentiating, Pre LPM working set 20150418, Protein, Surface, Targeting, THERAPY, THEROF, VCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology

Mononegavirales Vectors Expressing Chimeric Antigens

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use...

Published: 7/25/2024 | Inventor(s): Linda Brock, Ursula Buchholz, Peter Collins, Shirin Munir

Keywords(s): Added, Attenuated, DA4BXX, DA4XXX, DC5BXX, DC5XXX, DCXXXX, DD1XXX, DDXXXX, DEXXXX, DXXXXX, Expressing, F, Fusion, Gene, Highly, Human, Immunogenic, Macaques, MPV, Murine, PNEUMONIA, Protein, respiratory, RHESUS, RSV, Syncytial, virus

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease

Reducing Bloodstream Neutrophils as a Treatment for Lung Infection and Inflammation

During lung infection, bloodstream neutrophils (PMNs) responding to infection travel to the airspace lumen. Although successful arrival of microbicidal PMNs to the airspace is essential for host defense against inhaled pathogens, excessive accumulation of PMNs in the lung contributes to the pathogenesis of several prevalent lung disorders, including...

Published: 7/25/2024 | Inventor(s): Carmen Williams, Wan-Chi Lin, Michael Fessler

Keywords(s): 2, BARRIER, DA1XXX, DA3XXX, DA4XXX, DAXXXX, DBXXXX, During, DXXXXX, Epithelial, Infection, Inflammation, INTEGRITY, LUNG, MEMBRANE, PROTECT, Protein, respiratory, Targeting, VJXXXX, VKXXXX, VLXXXX, VPXXXX, WBXXXX, WJXXXX, WKXXXX, XAXXXX, YAXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Collaboration, ResearchProducts > Antibodies, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Infectious Disease, TherapeuticArea > Cardiology, TherapeuticArea > Dental, TherapeuticArea > Immunology, TherapeuticArea > Oncology

Resurfaced Stabilized Core 3 (RSC3) Protein, Derived Proteins, and DNA Encoding These Proteins: RSC3, RSC3 delta371I, RSC3 delta371I/P363N, RSC3 G367R

Details for these materials may be found in the NIH AIDS Reagent Program Catalog – RSC3 (Catalog# 12042): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=214 RSC3 delta371I (Catalog# 12043): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=146 RSC3 delta371I/P363N (Catalog# 12362): https://www.aidsreagent.org/reagentdetail.cfm?t=proteins&id=145 RSC3...

Published: 7/25/2024 | Inventor(s): Tongqing Zhou, Gary Nabel, Zhi-yong Yang, Ling Xu, Peter Kwong

Keywords(s): 3, Core, DERIVED, DNA, Encoding, Protein, proteins, Resurfaced, RM, RSC3, Stabilized, THESE, WIXXXX

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Materials Available, Application > Research Materials

Mononegavirales Vectors expressing Chimeric Antigens

Human respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not...

Published: 7/25/2024 | Inventor(s): Peter Collins, Ursula Buchholz, Linda Brock, Shirin Munir

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Vaccines, TherapeuticArea > Infectious Disease

Protein Nanoparticles for Antigen Display in Vaccines

The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to...

Published: 7/25/2024 | Inventor(s): Dustin McCraw, Audray Harris

Keywords(s): ANTIGEN, DC5BXX, DISPLAY, INFLUENZA, Nanoparticles, Protein, Vaccine, virus

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Materials Available, Application > Vaccines, TherapeuticArea > Infectious Disease

1 2 3 4